BMP2 and Legg-Calve-Perthes disease: Initial studies have investigated agents like MR16-1 (6), tocilizumab (26), strontium ranelate (43), ibandronate, and bone morphogenetic protein-2 (BMP-2) (44) in LCPD animal models.